background
pcrbase
detect
identif
virus
assum
known
rel
stabl
genom
unfortun
high
mutat
rate
may
lead
extens
chang
viral
nucleic
acid
sequenc
make
dedic
pcr
primer
use
problemat
furthermor
bioterror
viral
consensu
sequenc
genet
modifi
countermeasur
rtpcr
dna
chip
detect
accordingli
great
need
develop
rapid
univers
viru
detect
identif
technolog
rel
benign
virus
convert
highli
virul
virus
via
introduct
gene
interest
exampl
ectromelia
viru
natur
pathogen
mice
caus
mousepox
recent
recombin
part
effort
develop
live
viru
immunocontracept
vaccin
surprisingli
recombin
viru
caus
mortal
strain
mice
wherea
wild
type
viru
caus
death
credibl
bioterror
scenario
might
entail
releas
recombin
chimer
viru
tailor
maximum
infect
pathogen
readili
detect
use
current
stateoftheart
diagnost
ie
pcr
microarray
chip
accordingli
need
method
identifi
unknown
viral
pathogen
reveal
extens
genom
inform
method
would
prove
use
defens
bioterror
also
would
improv
capac
identifi
control
outbreak
natur
occur
pathogen
virus
proven
technolog
rapidli
detect
identifi
known
human
pathogen
potenti
caus
diseas
bioweapon
pcr
recent
exampl
involv
case
fatal
yellow
fever
yf
travel
return
amazona
brazil
march
otherwis
healthi
male
develop
fever
headach
pancytopenia
coagulopathi
renal
liver
failur
pancultur
neg
peripher
smear
yield
plasmodia
serolog
test
igg
igm
perform
cdc
neg
yf
dengu
st
loui
enceph
agent
serum
specimen
unfortun
examin
postmortem
posit
yf
viral
rna
measur
rtpcr
subsequ
attempt
isol
cultur
viru
fail
exampl
highlight
superior
pcr
current
avail
method
dna
chip
allow
simultan
measur
liter
thousand
gene
hybrid
develop
nextgener
rapid
diagnost
test
known
human
pathogen
howev
technolog
reli
rel
stabl
genom
sever
human
pathogen
display
high
mutat
rate
eg
hiv
base
kb
genom
moreov
abil
recombin
nonpathogen
virus
vitro
introduc
potenti
de
novo
pathogen
also
enhanc
stealth
consider
suggest
may
imposs
design
dna
microarray
detect
nucleic
acid
known
unknown
virus
includ
less
obviou
vehicl
bioterror
adenoviru
rhinoviru
recombin
singl
gene
enhanc
virul
accordingli
great
need
develop
techniqu
enabl
univers
amplif
viral
nucleic
acid
strategi
amplifi
genet
sequenc
pcr
without
prior
knowledg
precis
sequenc
first
strategi
reli
degener
bind
arbitrarili
chosen
primer
sampl
multipl
cdna
genom
dna
speci
pcr
two
relat
method
known
differenti
display
rna
arbitrarili
prime
pcr
rappcr
amplicon
rang
size
bp
overlap
rappcr
recent
use
success
identifi
novel
human
pneumoviru
viru
cultur
techniqu
yield
amplicon
fingerprint
gener
use
compar
two
popul
nucleic
acid
accordingli
pneumoviru
identifi
compar
infect
cell
noninfect
cell
strategi
known
sequenceindepend
singleprim
amplif
sispa
involv
direct
ligat
linkeradaptor
oligonucleotid
onto
end
target
popul
either
ds
dna
ds
cdna
revers
transcript
rna
pcr
accomplish
primer
specif
link
adaptor
molecul
sispa
follow
extens
immunoscreen
enabl
clone
norwalk
agent
genom
stool
hepat
g
viru
plasma
unfortun
techniqu
found
great
util
direct
discoveri
identif
novel
virus
human
plasma
serum
sampl
unless
accompani
immunoscreen
rel
high
level
host
genom
dna
howev
recent
studi
indic
dnase
treatment
serum
sampl
degrad
host
genom
dna
affect
viral
nucleic
acid
protect
stabl
capsid
combin
dnase
treatment
sispa
success
use
identifi
sequenc
entireti
novel
parvovirus
bovin
serum
aforement
pcr
techniqu
use
discoveri
novel
virus
util
rapidli
detect
identifi
unknown
recombin
virus
quit
limit
rappcr
random
rtpcr
sispa
complic
multistep
procedur
requir
infect
cultur
cell
day
accomplish
expens
reagent
broad
technic
expertis
accordingli
method
found
clinic
util
rapid
detect
identif
viral
agent
present
novel
method
rapid
viru
detect
identif
base
random
multiplex
rt
pcr
use
random
primer
avoid
primerdim
amplif
detect
viru
amplif
product
shotgun
clone
sequenc
identif
method
may
prove
use
rapid
detect
identif
emerg
recombin
virus
hypothes
random
amplif
viral
nucleic
acid
isol
human
plasma
might
provid
power
new
method
detect
identifi
novel
recombin
virus
alland
et
al
recent
found
subject
bovin
plasma
filtrat
remov
cell
dnase
treatment
remov
genom
dna
suffici
separ
viral
nucleic
acid
bovin
nucleic
acid
thu
enabl
sispa
clone
novel
virus
mechan
effect
relat
rel
sensit
freehost
dna
dnase
treatment
rel
insensit
viru
capsidprotect
dna
dnase
treatment
found
human
plasma
replet
free
dna
rna
speci
thu
opt
examin
potenti
dnase
rnase
treatment
isol
viral
nucleic
acid
inocul
human
plasma
adenoviru
type
examin
effect
filtrat
dnase
treatment
rnase
treatment
adenoviru
type
dna
human
genom
dna
mrna
use
rt
pcr
figur
demonstr
filtrat
dnase
rnase
treatment
increas
effici
amplif
adenoviru
type
dna
wherea
combin
treatment
elimin
amplif
genom
upper
band
cdna
lower
band
although
addit
rnase
alon
littl
effect
mrna
combin
dnase
rnase
complet
elimin
mrna
postul
find
may
relat
protect
rna
speci
dna
rna
hybrid
nevertheless
data
demonstr
abl
remov
host
dna
mrna
without
degrad
adenoviru
type
dna
next
design
mixtur
random
primer
would
enabl
prime
amplif
dna
cdna
molecul
would
resist
primerdim
amplif
chose
base
pair
compromis
length
simultan
optim
hybrid
possibl
bind
site
taq
polymeras
requir
three
base
primer
complementari
order
enabl
effici
polymer
postul
lock
end
primer
adenosin
incorpor
thymidin
upstream
portion
primer
would
prevent
primerdim
amplif
ie
v
g
c
primer
design
limit
frequenc
bind
site
within
particular
viral
genom
use
editseq
dna
edit
applic
dnastar
observ
primer
within
mixtur
bind
everi
bp
orient
viral
genom
examin
thu
provid
ampl
hybrid
amplif
potenti
first
test
random
primer
employ
dna
plasmid
known
sequenc
found
mixtur
primer
enabl
continuum
discret
pcr
product
amplifi
differ
circular
dna
plasmid
figur
shotgun
clone
pcr
product
confirm
amplifi
dna
deriv
sourc
plasmid
data
shown
contrast
primer
consist
sequenc
n
g
c
enabl
product
discret
clonabl
pcr
amplicon
figur
examin
abil
primer
pcr
amplifi
plasmid
pbabe
found
could
amplifi
littl
fg
figur
inocul
ml
human
plasma
adenoviru
type
plasma
filter
nm
filter
incub
hour
nucleas
remain
nucleic
acid
purifi
pcr
amplifi
use
primer
found
mixtur
primer
enabl
discret
pcr
product
amplifi
human
plasma
inocul
adenoviru
type
treat
filtrat
dnase
rnase
treatment
figur
importantli
observ
minim
amplif
product
uninocul
plasma
next
shotgun
clone
pcr
amplicon
topo
clone
vector
pcr
screen
coloni
e
coli
transform
mixtur
recombin
plasmid
uninocul
plasma
sampl
unabl
clone
sequenc
amplicon
data
shown
subsequ
experifiltr
nucleas
treatment
improv
viral
dna
amplif
remov
host
dna
mrna
figur
filtrat
nucleas
treatment
improv
viral
dna
amplif
remov
host
dna
mrna
human
plasma
inocul
adenoviru
type
suspens
filter
incub
hr
either
u
dnase
u
rnase
indic
remain
nucleic
acid
purifi
qiaamp
ultrassen
viru
kit
subject
st
strand
cdna
synthesi
cycl
pcr
use
primer
specif
either
adenoviru
type
human
dna
upper
band
primer
cross
intron
cdna
lower
band
amplicon
visual
ethidium
bromid
impregn
agaros
gel
genom
cdna
filter
dnase
rnase
ment
variabl
success
obtain
random
multiplex
pcr
amplif
human
plasma
obtain
sequenc
total
uninocul
plasma
sequenc
align
known
sequenc
ncbi
nonredund
databas
blastn
search
conduct
howev
shotgun
clone
dna
amplifi
adenoviru
human
plasma
obtain
recombin
vector
clone
clone
match
adenoviru
type
see
repres
exampl
figur
data
demonstr
combin
filtrat
dnase
rnase
treatment
random
multiplex
pcr
allow
detect
identif
adenoviru
type
without
use
virusspecif
reagent
primer
antibodi
microarray
chip
suspens
adenoviru
type
receiv
atcc
quantifi
sensit
random
multiplex
pcr
method
thu
uncertain
order
gener
standard
curv
conduct
realtim
pcr
known
concentr
pcramplifi
adenoviru
type
genom
templat
use
adenoviru
type
primer
found
could
detect
littl
copiesml
templat
data
shown
subject
atcc
adenoviru
type
suspens
atcc
realtim
pcr
use
adenoviru
type
primer
found
could
readili
detect
genom
dna
data
shown
base
realtim
pcr
gener
known
concentr
adenoviru
type
genom
templat
gen
g
g
g
g
c
g
c
c
c
g
c
g
c
c
c
c
c
c
c
g
g
c
c
c
c
c
c
c
g
c
g
g
g
g
c
g
c
c
c
g
c
g
c
c
c
c
c
c
c
g
g
c
c
c
c
c
c
c
q
u
e
r
g
g
g
g
g
g
g
c
g
g
g
g
g
g
c
g
g
c
g
g
c
g
g
c
g
c
b
j
c
g
g
g
g
g
g
g
c
g
g
g
g
g
c
g
g
c
g
g
c
g
g
c
g
c
q
u
e
r
g
c
g
g
c
g
c
c
c
g
g
g
g
g
g
g
c
g
g
c
c
g
c
c
g
g
c
g
g
g
g
g
b
j
c
g
c
g
g
c
g
c
c
c
g
g
g
g
g
g
g
c
g
g
c
c
g
c
c
g
g
c
g
g
g
g
g
q
u
e
r
c
c
c
c
c
g
g
g
g
g
c
g
c
g
c
c
g
g
g
g
g
c
c
b
j
c
c
c
c
c
c
g
g
g
g
g
c
g
c
g
c
c
g
g
g
g
g
c
c
q
u
e
r
c
g
g
g
g
g
g
g
g
c
c
c
g
c
g
g
g
c
g
c
g
g
c
g
g
g
g
c
g
c
g
c
c
g
g
g
g
g
g
g
g
c
c
c
g
c
g
g
g
c
g
c
g
g
c
g
g
g
g
c
g
c
g
q
u
e
r
g
g
g
g
g
c
c
g
g
g
g
g
c
c
c
c
c
g
c
g
c
g
g
c
c
g
g
g
g
g
c
c
g
g
g
g
g
c
c
c
c
c
g
g
c
g
c
g
g
c
q
u
e
r
c
c
g
c
g
g
g
g
g
g
g
g
g
b
j
c
c
c
g
c
g
g
g
g
g
g
g
g
g
erat
standard
curv
plot
concentr
adenoviru
type
genom
equival
versu
cycl
number
fluoresc
pass
preset
threshold
ct
figur
base
standard
curv
determin
stock
solut
adenoviru
type
contain
genom
equivalentsml
titrat
concentr
viru
human
plasma
conduct
combin
filtrat
dnasernas
treatment
random
multiplex
pcr
use
primer
found
random
multiplex
rt
pcr
method
sensit
genom
equivalentsml
figur
postul
random
multiplex
pcr
method
would
also
detect
rna
virus
viral
nucleic
acid
first
subject
st
strand
cdna
synthesi
inocul
human
plasma
rna
viru
coxsackieviru
csv
filter
treat
dnase
rnase
purifi
remain
nucleic
acid
conduct
rt
pcr
use
two
commerci
avail
revers
transcriptas
omniscript
superscript
ii
csv
specif
primer
separ
either
bp
kb
found
wherea
omniscript
rt
effici
amplifi
bp
cdna
speci
superscript
ii
rt
effici
amplifi
kb
fragment
figur
next
use
primer
random
multiplex
pcr
amplifi
cdna
observ
distinct
albeit
faint
amplicon
figur
clone
amplif
product
found
amplifi
dna
product
match
sequenc
clone
rna
genom
determin
blastn
align
search
ncbi
nonredund
databas
figur
surpris
clone
dna
coxsackieviru
align
known
sequenc
coxsackieviru
learn
coxsackieviru
strain
fulli
sequenc
thu
ncbi
nonredund
databas
search
term
coxsackieviru
accordingli
amplifi
portion
coxsackieviru
genom
previous
sequenc
figur
also
inocul
human
plasma
respiratori
syncyti
viru
b
abl
amplifi
identifi
genom
rna
use
primer
data
shown
howev
pcr
amplif
effici
poor
rna
virus
rel
dna
viru
suspect
may
relat
effici
revers
transcriptas
stabil
rna
novemb
outbreak
atyp
pneumonia
occur
guangdong
provinc
peopl
republ
china
diseas
respond
empir
antibiot
treatment
known
bacteri
viral
pathogen
identifi
use
serolog
rt
pcr
analys
disord
call
sever
acut
respiratori
syndrom
sar
juli
caus
report
case
fatal
effort
identifi
caus
agent
sar
sar
aetiolog
studi
group
coordin
distribut
inform
infect
materi
analys
data
realtim
pcr
quantit
adenoviru
type
dna
templat
figur
realtim
pcr
quantit
adenoviru
type
dna
templat
pcramplifi
genom
dna
adenoviru
type
quantit
spectrophotometri
od
nm
genom
equivalentsml
calcul
base
avogadro
number
mol
realtim
pcr
conduct
adenoviru
type
specif
primer
use
genom
equivalentsml
templat
use
stock
solut
adenoviru
type
templat
standard
curv
produc
base
threshold
cycl
number
test
concentr
adenoviru
type
dna
templat
plot
compar
threshold
cycl
number
c
stock
solut
adenoviru
type
b
indic
genom
equival
adenoviru
type
ad
ml
human
plasma
treat
nm
filtrat
dnasernas
digest
total
nucleic
acid
purifi
amplifi
random
multiplex
pcr
cycl
sequenc
describ
method
section
cycl
number
ct
amongst
eleven
separ
laboratori
research
cultur
fetal
rhesu
kidney
cell
infect
nasopharyng
aspir
conduct
random
rtpcr
use
primer
revers
transcript
pcr
uniqu
pcr
product
infect
cell
prepar
clone
sequenc
homolog
found
bovin
coronaviru
rtpcr
hundr
infect
clinic
specimen
use
primer
specif
novel
viru
confirm
identif
approach
success
worthwhil
note
requir
month
laboratori
identifi
viru
contrast
procedur
describ
herein
least
theoret
capabl
identifi
unknown
viru
without
use
special
design
primer
furthermor
possibl
least
partial
identifi
unknown
agent
within
day
one
laboratori
without
intermedi
cultur
step
current
studi
detect
identifi
separ
virus
ie
adenoviru
type
coxsackieviru
respiratori
syncyti
viru
b
use
novel
approach
random
multiplex
rt
pcr
purifi
viral
nucleic
acid
detect
accomplish
hour
use
microcentrifug
pcr
machin
requir
virusspecif
reagent
sensit
genom
equivalentsml
adenoviru
type
sensit
virusspecif
pcr
genom
equivalentsml
adequ
detect
free
viru
untreat
individu
coupl
potenti
direct
sequenc
inform
confid
approach
may
prove
use
defens
act
bioterror
well
detect
character
novel
virus
blood
product
patient
display
hallmark
infect
eg
leukocytosi
fever
although
believ
method
adequ
current
form
test
clinic
specimen
random
blind
diagnost
trial
consid
certain
altern
approach
may
yield
method
improv
sensit
specif
particular
intend
decreas
background
amplif
variabl
observ
order
prevent
fals
posit
increas
sensit
appli
sybr
green
fluoresc
dna
detect
final
appli
optim
approach
blood
specimen
viral
infect
patient
order
detect
unsuspect
variabl
valid
method
within
clinic
environ
longterm
goal
provid
emerg
room
primari
care
physician
abil
univers
detect
virus
human
plasma
rational
part
emerg
recombin
pathogen
viru
intent
releas
popul
abil
physician
detect
pathogen
crucial
contain
second
relat
applic
techniqu
involv
identif
previous
undescribedbut
natur
occur
virus
patient
suffer
idiopath
diseas
state
possibl
viral
etiolog
third
applic
procedur
may
screen
blood
bank
blood
presenc
viru
although
precis
identif
viru
requir
clone
sequenc
amplif
pattern
provid
clinic
laboratori
servic
emerg
room
primari
care
clinic
possess
abil
conduct
rtpcr
known
virus
hiv
unmodifi
random
multiplex
rt
pcr
method
requir
technic
expertis
conclus
optim
test
random
multiplex
rt
pcr
technolog
allow
develop
univers
viru
detect
assay
vastli
improv
collect
defens
viral
bioweapon
emerg
heretofor
unidentifi
natur
virus
plasmid
isol
viru
plasma
ml
blood
plasma
viru
cool
room
temperatur
place
ml
tube
viral
isol
carri
accord
manufactur
protocol
qiagen
viral
dna
rna
elut
column
final
volum
elut
buffer
product
either
use
directli
random
pcr
use
revers
transcript
reaction
revers
transcript
carri
accord
manufactur
protocol
either
omniscript
rt
qiagen
superscript
ii
rt
invitrogen
maximum
amount
viral
rna
use
place
water
reaction
pcr
viral
dna
isol
whole
blood
done
accord
method
describ
util
primer
product
run
agaros
gel
contain
ethidium
bromid
band
differ
water
control
excis
dna
extract
use
qiaquick
gel
extract
kit
qiagen
dna
elut
final
volum
elut
buffer
dna
clone
topo
clone
vector
invitrogen
follow
manufactur
protocol
transform
carri
top
chemic
compet
e
coli
result
coloni
pick
randomli
mix
pb
mixtur
use
pcr
reaction
use
univers
forward
revers
primer
pcr
master
mix
promega
follow
paramet
use
coloni
screen
minut
cycl
second
second
minut
pcr
product
run
agaros
gel
contain
ethidium
bromid
coloni
yield
product
greater
bp
grown
lb
broth
overnight
dna
isol
accord
manufactur
protocol
qiagen
elut
dna
final
volum
dna
sequenc
use
univers
forward
revers
primer
univers
louisvil
core
sequenc
facil
result
sequenc
screen
use
blast
program
ncbi
web
site
determin
sequenc
origin
pcr
carri
either
viral
dna
cdna
use
pcr
master
mix
promega
viral
dna
primer
use
reaction
total
volum
equal
per
reaction
follow
paramet
use
viralspecif
amplif
minut
second
second
minut
repeat
time
minut
gener
viral
dna
templat
real
time
pcr
viral
dna
isol
whole
blood
plasma
use
gener
templat
use
real
time
pcr
dna
viru
use
platinum
pcr
master
mix
invitrogen
solut
templat
primer
outlin
total
volum
reaction
pcr
paramet
use
use
viralspecif
amplif
result
product
run
agaros
gel
contain
ethidium
bromid
band
excis
dna
elut
accord
manufactur
instruct
qiagen
real
time
pcr
sampl
run
cepheid
smart
cycler
omnimix
hs
reagent
cephi
packg
takara
resuspend
water
suffici
two
pcr
reaction
stock
viru
templat
primer
ad
mix
sampl
run
sec
sec
sec
total
cycl
molecular
weight
determin
dsdna
templat
gener
pcr
od
result
dna
also
record
od
divid
molecular
weight
product
result
equal
number
multipli
avogadro
number
molecul
mole
result
number
equal
number
viral
dna
molecul
per
microlit
